Skip to main content
For US Healthcare Professionals Only
Quick Links
Prescribing information
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI™ (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
Report an Adverse Event or Product Complaint
Email
1-844-599-CARE (2273)
Connect With an MSL
Connect With Us
Main navigation
Home
Our Science
Overview
Publications
Clinical Pipeline
Opportunities for Investigators
Disease Education
Overview
Dermatology
Epilepsy
Rare Disease
Rheumatology
Podcasts
Independent Medical Education
Congress Materials
Medical Information
Overview
Submit Medical Inquiry
HCP Resources
Slide Library
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI™ (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Home
Congress Materials
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
Back to search results
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
View PDF
For US Healthcare Professionals Only
For US Healthcare Professionals Only